Trade

with

Durata Therapeutics Inc
(NASDAQ: DRTX)
AdChoices
24.09
+0.41
+1.73%
After Hours :
24.09
0.00
0.00%

Open

23.63

Previous Close

23.68

Volume (Avg)

299.23k (592.54k)

Day's Range

23.56-24.09

52Wk Range

8.92-24.33

Market Cap.

645.07M

Dividend Rate ( Yield )

-

Beta

3.96

Shares Outstanding

26.78M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 0

    • Net Income

    • -62.14M

    • Market Cap.

    • 645.07M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 3.96

    • Forward P/E

    • -16.05

    • Price/Sales

    • -

    • Price/Book Value

    • 238.10

    • Price/Cash flow

    • -9.61

      • EBITDA

      • -58.38M

      • Return on Capital %

      • -65.46

      • Return on Equity %

      • -194.03

      • Return on Assets %

      • -65.46

      • Book Value/Share

      • 0.10

      • Shares Outstanding

      • 26.78M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Outperform
        • 1 Year Price Target

        • 23.00

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • -1.50

        • Cashflow Estimate

        • -1.25

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 82.75

            • Pre-Tax Margin

            • -

            • 39.38

            • Net Profit Margin

            • -

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 14.30

              • 0.76

              • Current Ratio

              • 3.76

              • 2.92

              • Quick Ratio

              • 3.14

              • 2.35

              • Interest Coverage

              • -18.49

              • 38.02

              • Leverage Ratio

              • 29.12

              • 2.21

              • Book Value/Share

              • 0.10

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -9.62

                • 196.08

                • P/E Ratio 5-Year High

                • -9.91

                • 634.30

                • P/E Ratio 5-Year Low

                • -2.71

                • 124.82

                • Price/Sales Ratio

                • -

                • 9.12

                • Price/Book Value

                • 232.56

                • 8.26

                • Price/Cash Flow Ratio

                • -9.61

                • 47.39

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -194.03

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -65.46

                    (-)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -98.51

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • -

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -56.97M
                  Operating Margin
                  -
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -9.61
                  Ownership

                  Institutional Ownership

                  93.77%

                  Top 10 Institutions

                  76.12%

                  Mutual Fund Ownership

                  18.05%

                  Float

                  58.33%

                  5% / Insider Ownership

                  0.62%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Oppenheimer Global Opportunities

                  •  

                    1,000,000

                  • 0.00

                  • 3.73

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    720,291

                  • 0.00

                  • 2.69

                  • Vanguard VIF Small Comp Gr

                  •  

                    351,900

                  • 38.94

                  • 1.31

                  • iShares Russell 2000 (AU)

                  •  

                    243,458

                  • -1.01

                  • 1.70

                  • Vanguard US Discoveries Fund

                  •  

                    203,899

                  • -2.25

                  • 0.76

                  • Vanguard Total Stock Mkt Idx

                  •  

                    201,930

                  • 0.00

                  • 0.75

                  • Hartford Small Cap Growth HLS Fund

                  •  

                    177,687

                  • 0.00

                  • 0.66

                  • Hartford SmallCap Growth Fund

                  •  

                    171,580

                  • 12.93

                  • 0.64

                  • Northwestern Mutual Ser Sm Cp Gr Stk

                  •  

                    138,790

                  • 0.00

                  • 0.52

                  • Fidelity Advisor® Biotechnology Fund

                  •  

                    129,737

                  • 0.00

                  • 0.48

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Domain Associates, LLC

                  •  

                    3,034,688

                  • 0.00%

                  • 11.39

                  • New Leaf Ventures II LP

                  •  

                    3,028,439

                  • 0.00%

                  • 11.37

                  • Aisling Capital Partners III LLC

                  •  

                    2,280,175

                  • -24.75%

                  • 8.56

                  • Aisling Capital LLC

                  •  

                    2,030,175

                  • -33.00%

                  • 7.58

                  • Wellington Management Company, LLP

                  •  

                    1,942,397

                  • +3.14%

                  • 7.25

                  • Orbimed Advisors, LLC

                  •  

                    1,785,714

                  • 0.00%

                  • 6.67

                  • Sofinnova Management VII, L.L.C.

                  •  

                    1,777,856

                  • -21.73%

                  • 6.67

                  • Quaker BioVentures Capital II, LLC

                  •  

                    1,533,333

                  • +15.00%

                  • 5.76

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Growth

                  Durata Therapeutics Inc was incorporated under the laws of the State of Delaware on November 4, 2009. The Company, along with its subsidiaries, is a development stage pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. The Company recently completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI. Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing.

                  Key People

                  Mr. Paul R. Edick

                  CEO/Director/President

                  Mr. Corey N. Fishman

                  CFO/Chief Accounting Officer/COO

                  Wendy L. Yarno

                  Director

                  Nicole Vitullo

                  Director

                  Mr. Brenton K. Ahrens

                  Director

                  • Durata Therapeutics Inc

                  • 200 South Wacker Drive

                  • Chicago, IL 60606

                  • USA.Map

                  • Phone: +1 312 219-7000

                  • Fax: -

                  • duratatherapeutics.com

                  Incorporated

                  2009

                  Employees

                  68

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: